- Home
- HP vs VRDN Comparison
HP vs VRDN Comparison
Compare HP & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HP | VRDN |
|---|---|---|
| Founded | 1920 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HP | VRDN |
|---|---|---|
| Price | $29.88 | $32.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | $25.27 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 1.7M | 1.6M |
| Earning Date | 11-17-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,746,013,000.00 | $70,789,000.00 |
| Revenue This Year | $8.54 | $26,477.48 |
| Revenue Next Year | $3.52 | $6.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 35.89 | ★ 23340.07 |
| 52 Week Low | $14.65 | $9.90 |
| 52 Week High | $37.30 | $33.34 |
Technical Indicators
Market Signals| Indicator | HP | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 70.14 | 65.86 |
| Support Level | $25.81 | $30.22 |
| Resistance Level | $30.46 | $33.49 |
| Average True Range (ATR) | 1.21 | 1.20 |
| MACD | 0.20 | -0.01 |
| Stochastic Oscillator | 92.35 | 74.81 |
Price Performance
Historical ComparisonAbout HP Helmerich & Payne Inc.
Helmerich & Payne Inc provides performance-driven drilling solutions and technologies that are intended to make hydrocarbon recovery safer and more economical for oil and gas exploration and production companies. The Company focus on the drilling segment of the oil and gas production value chain. Company operates in North America, Gulf of Mexico, and other international places such as Argentina, Australia, Bahrain, Colombia and the United Arab Emirates (UAE). Also own and operates a limited number of commercial real estate properties located in Tulsa, Oklahoma. It's real estate investments include a shopping center and of undeveloped real estate projects.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).